Antiviral response in vernal keratoconjunctivitis may be protective against COVID-19

Allergy. 2022 Jan;77(1):298-300. doi: 10.1111/all.15048. Epub 2021 Aug 21.

Authors

Andrea Leonardi¹, Umberto Rosani², Fabiano Cavarzeran¹, Philippe Daull³, Jean-Sebastien Garrigue³, Brun Paola⁴

Affiliations

¹ Department of Neuroscience, Ophthalmology Unit, University of Padua, Padova, Italy.
² Department of Biology, University of Padova, Padova, Italy.
³ Santen SAS, Evry, France.
⁴ Department of Molecular Medicine, Histology Unit, University of Padova, Padova, Italy.

No abstract available

Keywords: ACE2; COVID-19; SARS-CoV-2; antiviral factors; vernal keratoconjuntivitis.

Publication types

Letter

MeSH terms

Antiviral Agents / therapeutic use
COVID-19*
Conjunctivitis, Allergic* / drug therapy
Humans
Peptidyl-Dipeptidase A
SARS-CoV-2

Substances

Antiviral Agents
Peptidyl-Dipeptidase A

Grants and funding

Santen SAS